In addition, the targeted inhibition of IL-6 has been reported to promote T cell infiltration and enhance the efficacy of ICIs to treat colorectal and pancreatic cancers in recent studies [20, 21]. The gene discussed is IL6; the disease is pancreatic neoplasm.